Get the Stockscreener App
2.0848
3.86%
-0.1152
Edesa Biotech Inc stock is traded at $2.0848, with a volume of 4,214.
It is down -3.86% in the last 24 hours and down -44.68% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
See More
Previous Close:
$2.20
Open:
$2.1
24h Volume:
4,214
Relative Volume:
0.19
Market Cap:
$6.97M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-0.8273
EPS:
-2.52
Net Cash Flow:
$-6.25M
1W Performance:
-3.86%
1M Performance:
-44.68%
6M Performance:
-53.52%
1Y Performance:
-24.46%
1-Day Range:
$2.09
$2.1395
1-Week Range:
$2.05
$2.32
52-Week Range:
$2.05
$6.46
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| EDSA | 2.09 | 6.97M | 0 | -7.72M | -6.25M | -2.52 |
| VRTX | 448.24 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.59 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.88 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.69 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.79 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Edesa Biotech Inc Stock (EDSA) Latest News
EDSA stock touches 52-week low at $2.08 amid market challenges - Investing.com
EDSA stock touches 52-week low at $2.27 amid market challenges - Investing.com Canada
500: Something went wrong - Investing.com
Edesa Leaps as CEO Boosts Holdings - Baystreet.ca
Edesa Biotech CEO invests $5 million in company By Investing.com - Investing.com India
Edesa Biotech’s Founder Makes Strategic Investment in the Company - GlobeNewswire
Edesa Biotech to Present at Global Conferences - Nasdaq
Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewswire
Edesa Biotech Partners with Wainwright for Share Sales - TipRanks
Edesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38 - MSN
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? - MSN
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewswire Inc.
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
1 Dividend Stock to Invest in the Domestic Steel Market Now - The Globe and Mail
Celsius Holdings Inc (CELH-Q) QuotePress Release - The Globe and Mail
Mackenzie Investments Announces Results of Special Meetings on Mutual Fund and ETF Mergers - Yahoo Canada Finance
ECB interest rate cut likely as Eurozone economy weaker than expected - Yahoo Finance UK
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions - Yahoo Finance UK
Santander starts $1.7 billion share buyback programme - Yahoo Finance UK
FY2024 Earnings Estimate for Edesa Biotech, Inc. (NASDAQ:EDSA) Issued By HC Wainwright - Defense World
H.C. Wainwright bullish on Edesa Biotech stock amid BARDA study support - Investing.com
Edesa Biotech’s (EDSA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
EDSA: EB05 Selected for BARDA-Funded Study in ARDS… - Zacks Small Cap Research
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Stock Price Down 2% - Defense World
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - XM
Ethiopian Airlines posts 14% jump in full-year revenue - Yahoo Finance UK
Alexis Shamess | Corporate/Commercial Lawyer in Toronto | People - Fasken
Myroslav Chwaluk | Mergers & Acquisitions Lawyer in Toronto | People - Fasken
A. Wojtek BaraniakPolish-speaking Corporate/Commercial lawyer in Toronto | People - Fasken
MoneySmart’s June Lucky Draw 2024 - Yahoo Finance
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Yahoo Finance UK
Homebuilder Vistry boosts output target as cost inflation softens - Yahoo Finance UK
German environmental authorities approve Tesla site expansion - Yahoo Finance UK
Cipher Pharmaceuticals - The Pharma Letter
Edesa Biotech (NASDAQ:EDSA) Receives Buy Rating from HC Wainwright - Defense World
Allied gaming executive Choi buys shares worth $778k By Investing.com - Investing.com
Bioventus exec sells over $14k in company stock By Investing.com - Investing.com
Edesa's Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS - Contract Pharma
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - StockTitan
Edesa’s Paridiprubart Selected For U.S.-Funded Platform Trial In General ARDS - Contract Pharma
Comparing Assertio (NASDAQ:ASRT) and Edesa Biotech (NASDAQ:EDSA) - Defense World
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Rises By 32.1% - Defense World
Perritt Capital Management Inc. Has $482000 Stake in Usio, Inc. (NASDAQ:USIO) - Defense World
Anixa Biosciences director buys shares worth over $1,000 By Investing.com - Investing.com
Stephens Inc. AR Has $1.30 Million Stock Holdings in DuPont de Nemours, Inc. (NYSE:DD) - Defense World
French jet engine maker Safran gets Italy's clearance to buy Microtecnica - Yahoo Finance UK
Edesa Biotech Shareholders Approve Board and Compensation PlansTipRanks.com - TipRanks
Edesa Biotech, Inc. Forecasted to Earn FY2024 Earnings of ($1.95) Per Share (NASDAQ:EDSA) - Defense World
FY2024 EPS Estimates for HEICO Co. Lifted by Analyst (NYSE:HEI) - Defense World
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):